The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

Novo Nordisk A/S’s weight-loss and diabetes drugs are no longer in short supply, US regulators said, a decision that’s expected to curtail widespread access to cheaper copies of the popular ...

The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk's popular weight-loss and ...

Shares of Hims & Hers Health (NYSE:HIMS) are down about 21%, or $14. All on news the Ozempic shortage is over. Key Points ...

Swiss drugmaker Roche began a study last year of its experimental drug, RG6237, as a monotherapy in people with high body ...

The three sites in Anagni, Italy, Brussels in Belgium, and Bloomington, Indiana, in the US will change ... as Novo Nordisk has been struggling to meet the demand for diabetes therapy Ozempic ...

Given it also now has an activist investor - Elliott Investment Management - with a 5% stake, some sort of structural change ... 2025 Novo Nordisk’s blockbuster GLP-1 diabetes drug Ozempic ...

Current weight-loss methods such as lifestyle changes, surgery, and popular therapies like Novo Nordisk's Wegovy and ... acquisition -- with a main goal of change in total body weight.

Saxenda – which comes as prefilled self-injection pen – will ... injectable Ozempic (semaglutide) which grew 119% to DKK 15 billion ($2.35 billion), overtaking Novo Nordisk’s older Victoza ...